Swedish Orphan Biovitrum AB (Sobi™) today announced that Milan Zdravkovic has been appointed Senior Vice President, Head of Research & Development (R&D).
Milan joins Sobi from Novo Nordisk where he has had an 18 year tenure in the Research and Development organisation responsible for therapeutic areas including diabetes, growth hormone deficiency, obesity and immunology. Milan’s experience spans early stage development to post-approval life-cycle management in these areas. His most recent role was as Corporate Vice President, Obesity.
“We are delighted to welcome Milan to Sobi”, said Geoffrey McDonough, President and CEO at Sobi. “Milan brings a creative global translational and development profile which can build and expand upon our strong legacy of biologics innovation.”
Milan will lead Sobi’s R&D efforts from post-proof of concept to late life cycle development, focusing on advancing and expanding Sobi’s early and mid-stage pipeline under a unified innovation strategy. “I am looking forward to joining the team at Sobi and to advancing Sobi’s mission to develop and deliver innovative therapies to people with rare diseases,” said Milan. Milan will join Sobi on 1 November 2016.
Surce: Sobi
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
